[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pär Johansson\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100540625","phase-2-infusion-of-prostacyclin-vs-placebo-for-72-hours-in-mechanically-ventilated-patients-with-acute-respiratory-failure-100540625",false,"NCT06319274","Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure","Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 ng\u002Fkg\u002FMin) in Mechanically Ventilated Patients With Infectious Pulmonary Endotheliopathy - a Multicenter Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial","COMBAT-ARF","Inclusion Criteria:\n\n* Adult intensive care patients (age ≥ 18 years)\n* Suspected pulmonary infection\n* Need for mechanical ventilation (\\\u003C 24 hours from time of screening)\n* soluble thrombomodulin (sTM) ≥ 4 ng\u002FmL in blood plasma\n\nExclusion Criteria:\n\n* Withdrawal from active therapy\n* Pregnancy (non-pregnancy confirmed by patient having a negative urine- or plasma Choriogonadotropin (hCG) or being postmenopausal defined as females at 60 years old or beyond or at the investigators discretion)\n* Septic shock according to the Sepsis 3 criteria AND a sTM\\> 10 ng\u002Fml\n* Known hypersensitivity to iloprost or to any of the other ingredients.\n* Previously included in this trial or a prostacyclin trial within 30 days\n* Life-threatening bleeding defined by the treating physician\n* Known severe heart failure (NYHA class IV)\n* Suspected acute coronary syndrome","ALL","18 Years",{"count":20,"type":21},450,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this clinical trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in 450 mechanically ventilated patients with infectious respiratory failure. The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in patients suffering from respiratory failure caused by endothelial breakdown, ultimately improving survival.",[27,28,29],"Acute Respiratory Failure","Endothelial Dysfunction","Pulmonary Infection",[31,32],"Endotheliopathy","SHINE","RECRUITING","2025-08-18",{"date":36,"type":37},"2025-08-22","ACTUAL",{"date":39,"type":37},"2024-04-15",{"date":41,"type":21},"2027-09-30",{"name":43,"class":44},"Pär Johansson","OTHER",5,""]